계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Juventas
company
About
Juventas is a provider and developer of innovative immune cell therapeutic drugs.
- 11 - 50
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- ¥410M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2018
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Juventas is a provider and developer of innovative immune cell therapeutic drugs. The company's first investigational new drug application for the cell therapeutic product CNCT19 has been officially accepted by the National Medical Products Administration. Comprehensive product pipelines will be developed and promoted constantly to provide effective treatment for malignant hematological neoplasms such as leukemia and lymphoma.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
¥410M
Juventas has raised a total of
¥410M
in funding over 2 rounds. Their latest funding was raised on
Jul 12, 2021 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 12, 2021 | Series C | ¥410M | 4 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
4
Juventas is funded by 4 investors.
Haisong Capital
and Tianchuang Zhixing (Beijing) Touzi Guanli Zixun Youxian Gongsi
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series C |
|
|
— | Series C |
|
|
— | Series C |
Ding Xiang Capital
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
